Steigerwald Gordon & Koch Inc. lifted its stake in shares of  Johnson & Johnson (NYSE:JNJ) by 2.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 95,949 shares of the company's stock after buying an additional 2,145 shares during the quarter. Johnson & Johnson comprises  2.7% of Steigerwald Gordon & Koch Inc.'s portfolio, making the stock its 8th largest position. Steigerwald Gordon & Koch Inc.'s holdings in Johnson & Johnson were worth $16,949,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Lincoln Capital Corp grew its position in shares of  Johnson & Johnson by 15.9% in the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company's stock worth $218,000 after buying an additional 183 shares during the period.  Ieq Capital LLC boosted its stake in  Johnson & Johnson by 5.1% during the third quarter. Ieq Capital LLC now owns 128,012 shares of the company's stock worth $20,912,000 after acquiring an additional 6,154 shares in the last quarter.  RFG Advisory LLC grew its holdings in  Johnson & Johnson by 2.7% in the third quarter. RFG Advisory LLC now owns 22,434 shares of the company's stock worth $3,900,000 after purchasing an additional 594 shares during the period.  FDx Advisors Inc. lifted its holdings in shares of  Johnson & Johnson by 0.3% during the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company's stock valued at $8,237,000 after purchasing an additional 153 shares during the last quarter.  Finally, HM Payson & Co. boosted its position in shares of  Johnson & Johnson by 3.2% in the 3rd quarter. HM Payson & Co. now owns 783,538 shares of the company's stock worth $127,999,000 after purchasing an additional 24,188 shares in the last quarter. 67.94% of the stock is owned by institutional investors.

Get Johnson & Johnson alerts:

Insider Buying and Selling

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business's stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company's stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.35% of the stock is owned by insiders.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. StockNews.com assumed coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a "strong-buy" rating on the stock. Atlantic Securities lifted their target price on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a "neutral" rating in a report on Wednesday, January 25th. Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a "neutral" rating and a $161.00 price target on the stock. SVB Leerink decreased their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating for the company in a report on Friday, January 20th. Finally, Morgan Stanley increased their target price on Johnson & Johnson from $176.00 to $180.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 25th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one  has issued  a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $174.73.

Johnson & Johnson Stock Up 1.0 %

JNJ stock opened at $152.65 on Friday. The company has a market cap of $397.54 billion, a price-to-earnings ratio of 22.65, a P/E/G ratio of 2.60 and a beta of 0.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The business's 50-day moving average is $159.76 and its two-hundred day moving average is $167.55. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analysts' expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business's quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.13 EPS.  As a group, analysts forecast that  Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a $1.13 dividend. The ex-dividend date of this dividend  was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.96%. Johnson & Johnson's dividend payout ratio (DPR) is 67.06%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.

Read More

• Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)

• MarketBeat Week in Review – 3/20 – 3/24

• Dividend King Genuine Parts Company Upgraded On Profit Guidance

• The Bottom Is In For Accenture

• 11 Best Consumer Discretionary Stocks of 2023

• 5 Best Dividend Capture Stocks

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.